Active Ingredient(s): Peramivir
FDA Approved: * December 19, 2014
Category: Antiviral

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Rapivab Overview

Peramivir (trade name Rapivab) is an antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. It is approved for intravenous administration.[1] In October 2009, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the use of pera...

Read more Rapivab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Peramivir

Recent Rapivab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 200mg/20ml (10mg/ml)
  • Solution: 200mg/20ml (10mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Rapivab: (2 results)

Sorted by National Drug Code
  • 61364-181 Rapivab 600 mg/60ml Intravenous Solution by Biocryst Pharmaceuticals, Inc.
  • 65044-7495 Rapivab 600 mg/60ml Intravenous Solution by Jubilant Hollisterstier LLC

Other drugs which contain Peramivir or a similar ingredient: (1 result)